While serum NfL is an FDA-qualified biomarker, accumulating evidence indicates that BEV NfL increases earlier and more closely tracks corticospinal tract degeneration than serum NfL, suggesting substantial potential to reduce diagnostic latency, a finding emphasized in the 2024 EV-ALS biomarker compendium [90]. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.